In the field of intellectual property and the protection of results derived from our research and developments, we have filed patent PCT/EP2024/087311, titled “DHP-I Inhibitors for use as neuroprotectants and in the treatment of neuroinflammatory diseases”. This patent provides 20 years of protection, ensuring exclusivity until 2043. The patent covers cilastatin as a neuroprotective agent for the treatment of neuroinflammatory diseases such as glaucoma, and also encompasses new DHP-I enzyme inhibitors that may be developed in the future.
Our strategy is not limited to this initial patent. We plan to file additional patents covering pharmaceutical compositions and specific administration regimens of cilastatin for use in ophthalmology and other neurodegenerative diseases. This expansion of our patent portfolio will ensure comprehensive protection of our innovations, facilitating their long‑term application and commercialization.
In addition, TELARA has patented the use of cilastatin as a treatment for drug‑induced nephrotoxicity caused by various toxic compounds, as well as for sepsis. All patents related to nephroprotection have been exclusively licensed to the Canadian pharmaceutical company Arch Biopartners.
